Idera Pharmaceuticals Stock Forecast, Price & News

-0.04 (-3.25 %)
(As of 06/18/2021 01:14 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume29,886 shs
Average Volume2.16 million shs
Market Capitalization$59.54 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Idera Pharmaceuticals logo

About Idera Pharmaceuticals

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.49 out of 5 stars

Medical Sector

614th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

87th out of 198 stocks

Analyst Opinion: 4.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions

Is Idera Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Idera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IDRA, but not buy additional shares or sell existing shares.
View analyst ratings for Idera Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Idera Pharmaceuticals?

Wall Street analysts have given Idera Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Idera Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Idera Pharmaceuticals' next earnings date?

Idera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Idera Pharmaceuticals

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) released its quarterly earnings data on Thursday, April, 29th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.08.
View Idera Pharmaceuticals' earnings history

How has Idera Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Idera Pharmaceuticals' stock was trading at $1.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IDRA shares have decreased by 13.8% and is now trading at $1.19.
View which stocks have been most impacted by COVID-19

When did Idera Pharmaceuticals' stock split? How did Idera Pharmaceuticals' stock split work?

Shares of Idera Pharmaceuticals reverse split on Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for IDRA?

5 equities research analysts have issued 1-year price targets for Idera Pharmaceuticals' stock. Their forecasts range from $1.00 to $9.00. On average, they expect Idera Pharmaceuticals' stock price to reach $4.00 in the next year. This suggests a possible upside of 236.1% from the stock's current price.
View analysts' price targets for Idera Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the following people:
  • Mr. Vincent J. Milano, Pres, CEO & Director (Age 57, Pay $347.71k)
  • Mr. John J. Kirby, Sr. VP & CFO (Age 49, Pay $513.97k)
  • Mr. Bryant David Lim, Sr. VP, Gen. Counsel & Corp. Sec. (Age 50, Pay $514.23k)
  • Mr. Robert Clayton Fletcher, Consultant (Age 58, Pay $575.68k)
  • Mr. Daniel B. Soland, Sr. VP & COO (Age 65)
  • Ms. Jill Conwell, Sr. VP of Investor Relations & Corp. Communications
  • Ms. Elizabeth Eberhardt, Sr. VP of Product Leadership
  • Dr. Shah Rahimian, Medical Director & Global Clinical Lead for Oncology
  • Dr. Joanna C. Horobin M.B., Ch.B, Advisor (Age 66)
  • Dr. Sudhir Agrawal, Scientific Advisor (Age 67)

What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO?

7 employees have rated Idera Pharmaceuticals CEO Vincent Milano on Vincent Milano has an approval rating of 88% among Idera Pharmaceuticals' employees.

Who are some of Idera Pharmaceuticals' key competitors?

What other stocks do shareholders of Idera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include (OAS), BioCryst Pharmaceuticals (BCRX), Sorrento Therapeutics (SRNE), Novavax (NVAX), Dynavax Technologies (DVAX), Proteostasis Therapeutics (PTI), Geron (GERN), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO) and Anavex Life Sciences (AVXL).

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (4.09%), BlackRock Inc. (1.27%), Geode Capital Management LLC (0.52%), Acadian Asset Management LLC (0.43%), Virtu Financial LLC (0.29%) and Hollencrest Capital Management (0.33%). Company insiders that own Idera Pharmaceuticals stock include Bryant David Lim, Daniel B Soland, Elizabeth Ann Tarka, Invest Corp Pillar, John J Kirby, Jonathan Michael Yingling, Robert C Fletcher and Vincent Milano.
View institutional ownership trends for Idera Pharmaceuticals

Which major investors are selling Idera Pharmaceuticals stock?

IDRA stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, and Renaissance Technologies LLC. Company insiders that have sold Idera Pharmaceuticals company stock in the last year include Bryant David Lim, Elizabeth Ann Tarka, John J Kirby, and Vincent Milano.
View insider buying and selling activity for Idera Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Idera Pharmaceuticals stock?

IDRA stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Virtu Financial LLC, Morgan Stanley, Geode Capital Management LLC, HRT Financial LP, Hollencrest Capital Management, Wade G W & Inc., and Advisory Services Network LLC. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Daniel B Soland, and Invest Corp Pillar.
View insider buying and selling activity for Idera Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $1.19.

How much money does Idera Pharmaceuticals make?

Idera Pharmaceuticals has a market capitalization of $59.54 million and generates $1.45 million in revenue each year. The biotechnology company earns $-112,660,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

How many employees does Idera Pharmaceuticals have?

Idera Pharmaceuticals employs 32 workers across the globe.

When was Idera Pharmaceuticals founded?

Idera Pharmaceuticals was founded in 1989.

What is Idera Pharmaceuticals' official website?

The official website for Idera Pharmaceuticals is

Where are Idera Pharmaceuticals' headquarters?

Idera Pharmaceuticals is headquartered at 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at 484-348-1600 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.